Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors (6:27).
00:00 Background to the studies
01:42 Key findings from BE OPTIMAL
02:59 Key findings from BE COMPLETE
04:22 How the results compare
04:43 Bimekizumab safety
04:55 Relevance for clinical practice